Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment

The latest announcement is out from Karyopharm Therapeutics ( (KPTI) ).

At the 2025 Annual Meeting of Stockholders held on May 28, Karyopharm Therapeutics Inc. announced that its stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available by 450,000. Additionally, Garen G. Bohlin and Zhen Su were elected as Class III directors for a three-year term. The stockholders also approved the compensation of the company’s named executive officers and recommended annual advisory votes on this compensation. Furthermore, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Spark’s Take on KPTI Stock

According to Spark, TipRanks’ AI Analyst, KPTI is a Underperform.

Karyopharm Therapeutics’ overall stock score reflects substantial financial challenges, including negative equity and cash flow issues, which are significant risks. While there are promising developments in clinical trials, such as the SENTRY trial and selinexor’s potential, these are offset by immediate financial pressures and a bearish technical outlook. The lack of profitability and dividend further weighs down the stock’s attractiveness.

To see Spark’s full report on KPTI stock, click here.

More about Karyopharm Therapeutics

Karyopharm Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of novel drugs for the treatment of cancer and other major diseases.

Average Trading Volume: 122,436

Technical Sentiment Signal: Sell

Current Market Cap: $39.31M

See more insights into KPTI stock on TipRanks’ Stock Analysis page.